AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05127265 — intervention group
Intervention type: OTHER
Intervention: Vitals Monitoring
Description: continuous vitals monitoring (heart rate, oxygen saturation)
Study NCT05127265 — intervention group
Intervention type: OTHER
Intervention: Biosample Collection
Description: blood and urine samples collected once on Day 1 and once on Day 2
Study NCT05127265 — intervention group
Intervention type: OTHER
Intervention: Delirium Motor Subtyping Scale 4 (DMSS-4)
Description: done daily on delirious patients to subtype delirium
Study NCT05699018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: eLIFT
Description: Diagnostic procedure: elastography devices, blood tests (e-LIFT + Fibrometer), liver biopsy if necessary (elastometry ≥ 8 kPa and \< 15 kPa)
Study NCT05565924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.
Description: Moderate-intensity aerobic exercise training on the antigravity treadmill (100% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination).
Study NCT05565924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.
Description: Moderate-intensity aerobic exercise training on the antigravity treadmill (70% weight-bearing) plus medications plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)
Study NCT05565924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.
Description: Moderate-intensity aerobic exercise training on the antigravity treadmill (50% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)
Study NCT05565924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group- D (30% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.
Description: Moderate-intensity aerobic exercise training on the antigravity treadmill (30% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination).
Study NCT05565924 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Group- E; Control group
Description: Control: No aerobic exercise training on the antigravity treadmill, but only medications (Biguanide alone or Sulfonylureas plus Biguanide combination) throughout the study.
Study NCT06649435 — intervention group
Intervention type: PROCEDURE
Intervention: PPG measurement
Description: PPG signal will be measured on CE certified medical devices. Two measurements will be performed - standing and in the recumbent position using reflectance and transmitance method on finger and in ear canal. The each measurement will be 120s long.~Detailed analysis of PPG signal and pathophysiological phenomena associated with HF - peripheral volume changes detectable in PPG signal - will help to understand better and clarify the pathophysiological mechanisms of peripheral volume changes in a failing heart.
Study NCT06206291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo twice daily for first 4 weeks
Study NCT06206291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) 200mg
Description: First 4 weeks: CBD (200mg)/Placebo twice daily adjunct with opioid agonist treatment.
Study NCT06206291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) 400mg
Description: Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.
Study NCT06206291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol (CBD) 400mg
Description: Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.
Study NCT05322967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time of ordinary antihypertensive medication intake
Description: Time of ordinary antihypertensive medication intake
Study NCT04373122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBOA
Description: Resuscitative Endovascular Balloon Occlusion of the Aorta
Study NCT05117801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Petale
Description: The child sits on the companion's lap between the two enclosures, and the investigator observes whether or not he is attracted to a familiar calibrated noise coming from one side or the other.
Study NCT00629213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04821011 — intervention group
Intervention type: DEVICE
Intervention: electronic stethoscope
Description: Record of maternal heart sounds (heartbeats) with an electronic stethoscope during 10 minutes.
Study NCT04821011 — intervention group
Intervention type: DEVICE
Intervention: acoustic listening of mother's heartbeats
Description: Each newborn included will have 20 minutes of an acoustic listening of their mother heartbeats previously recorded.
Study NCT04821011 — intervention group
Intervention type: DEVICE
Intervention: Recording of the newborn's heart rate
Description: Recording of the newborn's heart rate: one hour before the acoustic listening, during the acoustic listening and one hour after the acoustic listening .~The variations of the autonomic nervous system will be analyzed.~An coupled Heart rate variability recording (ECG signal obtained from a Philips® IntelliVue MX700 monitor) and NIPΣ index of comfort (MDMS® NIPΣ monitor) will be used.
Study NCT06302335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Description: Application of Povidone-iodine to the surgical wound of patients submitted to colorectal resections.
Study NCT06302335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: Application of saline solution to the surgical wound of patients submitted to colorectal resections.
Study NCT06309758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breinzorg
Description: The BreinZorg multidomain lifestyle website comprises 16 domains, namely (1) physical activity, (2) healthy diet, (3) smoking, (4) alcohol, (5) sleep, (6) cognitive activity (7) social activity, (8) diabetes, (9) blood pressure, (10) cholesterol, (11) heart- and vascular diseases, (12) kidney diseases, (13) hearing damage, (14) obesity, (15) anxiety, and (16) depression. These 16 modules are separated into three big themes: mood, lifestyle, and body.~Each module consists of the following:~1. General information on the risk factor;~2. Tips on how to improve and decrease the risk;~3. Quiz questions about the risk factor, giving extra knowledge/ in a playful and interactive manner;~4. Examples of SMART goals fitting the risk factor (goal examples are given in a Specific, Measurable, Achievable, Relevant, and Time-Bound manner).
Study NCT04747145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 60 Gy to be delivered over 30 daily treatments in six weeks. Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
Study NCT04747145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemotherapy (Temozolomide)
Description: 75mg/m\^2 x 42 days (concurrent chemotherapy with radiation). Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
Study NCT04747145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy (Temozolomide)
Description: Starting no sooner than 4 weeks after completion of chemoradiation, 150-200mg/m\^2, days 1-5 of 28-day cycle, for minimum of six cycles and up to 12 cycles.
Study NCT05292365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RE-PACT Intervention
Description: * Create respiratory illness action plan~* Weekly mHealth text messages~* Monthly study assessments~* Action planning and JIT coaching
Study NCT05255757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Script Intervention
Description: This intervention provides language to participants to allow them to discuss kidney transplantation with their social network.
Study NCT05255757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search Intervention
Description: This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, and be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation.
Study NCT05831085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: State-of-the-Art Percutaneous Coronary Intervention
Description: supported by intracoronary imaging (e.g., intravascular ultrasound \[IVUS\] or optical coherence tomography \[OCT\]), intracoronary physiology (e.g., fractional flow reserve \[FFR\] or instantaneous wave-free ratio \[iFR\]), contemporary metallic drug-eluting stents (DES), guideline-directed optimal medical therapy \[GDMT\] with advanced cardiovascular and anti-diabetic medications \[e.g., a sodium-glucose cotransporter \[SGLT\]-2 inhibitors\]) in patients with type 2 diabetes and three-vessel coronary artery disease (CAD) (not involving left main)
Study NCT05831085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard CABG
Description: Coronary-Artery Bypass Grafting
Study NCT05085002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lerociclib + Letrozole or Fulvestrant
Description: All participants (1L and 2L populations) will receive an AI (letrozole) or fulvestrant plus lerociclib 150 mg BID.
Study NCT04690972 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample during surgery
Description: During the hepato-bilio-pancreatic surgery, blood is drawn.
Study NCT04690972 — intervention group
Intervention type: PROCEDURE
Intervention: Taking an additional biopsy
Description: As part of the treatment, an additional biopsy is executed and blood is drawn.
Study NCT05591703 — intervention group
Intervention type: BEHAVIORAL
Intervention: Clinical Outcomes and Questionnaires
Description: Clinical patient-reported outcomes will be administered remotely at specified timepoints. No treatment or intervention will be administered in this protocol.
Study NCT04932889 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease...), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc..., treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.
Study NCT04690972 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample during diagnostic test
Description: Blood sample as part of the care
Study NCT04983368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanamem® 5 mg
Description: Oral Xanamem® (UE2343) capsules 5 mg, administered orally once daily.
Study NCT04932889 — intervention group
Intervention type: OTHER
Intervention: Laboratory parameters
Description: The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.
Study NCT04932889 — intervention group
Intervention type: OTHER
Intervention: chest computed tomography
Description: Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).
Study NCT05732129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: 150mg,orally, bid (days 1-7) every 2 weeks
Study NCT05732129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 30-90min continuous infusion 180mg/m2 Irinotecan on day 1, q2w
Study NCT06421324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health reccommendations
Description: Patients are given recommendations according to their risk group, based on the model which already predicted health indicators. This information will be sent to the patient's treating physician so that treatment and recommendations are aligned with the clinical care practice based on the European Code of Cancer guidelines, the H. pylori best practices guidelines and European GIM guidelines
Study NCT04983368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.
Study NCT04983368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanamem® 10 mg
Description: Oral Xanamem® (UE2343) capsules 10 mg, administered orally once daily.
Study NCT03952299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Transdermal Patch
Description: Transdermal patch of oxybutynin will be used instead of oral oxybutynin.
Study NCT03952299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Oxybutynin
Description: Oral administration of oxybutynin (5mg) every 8 hours in the hospital.
Study NCT06246045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Walking test
Description: PERT will be activated by AI algorithm. As a result of the discussion, patients will either be determined to be appropriate for immediate invasive strategy versus watchful waiting depending on whether high-risk PE criteria are met.~For those in the intermediate-high risk category, there remains ambiguity on timing and appropriateness of invasive intervention. On day 1 of admission, patients will undergo a walking test evaluating for abnormalities in heart rate, heart rate recovery, and oxygen need. If criteria is met, patients will be randomized in a 2:1 fashion (treatment versus control) to evaluate use of early-invasive strategy.
Study NCT06246045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Walking test
Description: PERT will be activated by AI algorithm. As a result of the discussion, patients will either be determined to be appropriate for immediate invasive strategy versus watchful waiting depending on whether high-risk PE criteria are met.~For those in the intermediate-high risk category, there remains ambiguity on timing and appropriateness of invasive intervention. On day 1 of admission, patients will undergo a walking test evaluating for abnormalities in heart rate, heart rate recovery, and oxygen need. If criteria is met, patients will be randomized in a 2:1 fashion (treatment versus control) to evaluate use of early-invasive strategy.
Study NCT05702151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP Block
Description: After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed. Ropivacaine 0.2% infusion at a 10ml/h rate is started during the surgery.
Study NCT05702151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine injection
Description: Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.
Study NCT05702151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine injection
Description: Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.
Study NCT05537064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-visit Based Intervention
Description: At the beginning of the study period, PCPs will be sent an Inbasket message, a secure electronic messaging system included in EPIC, similar to an email. The message will notify them that pended orders for a referral to centralized pharmacy services for statin management will be entered for eligible patients unless the provider opts out. If no opt-out is received from the PCP within 7 days of receiving the message, their eligible patient panels will be referred to a centralized pharmacy team to begin pending referral orders to the PCP for eligible patients. Pharmacists affiliated with the centralized pharmacy service will then enter pended orders for referral to centralized pharmacy services that PCPs can sign either individually or in bulk. After the PCP signs the order for referral to centralized pharmacy services, a pharmacist from the centralized pharmacy team will then reach out to the patient on behalf of their PCP and discuss their indication for statin therapy.
Study NCT05537064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit-Based Intervention
Description: The study team will build an interruptive BestPractice advisory (BPA), a pop-up notification in the EHR that is delivered to the PCP when they open the patient's chart during a non-acute patient visit. The BestPractice Advisory will describe the guideline criteria for which the patient is eligible for statin therapy, and recommend referral to a centralized pharmacy service for statin initiation and management. It will also include a link to a menu for prescribing an appropriate-dose statin, should the PCP want to prescribe a statin without referral to pharmacy services. The option for ordering referral to centralized pharmacy services will be pre-selected, such that if the PCP simply clicks Accept on the BPA, an order for referral to centralized pharmacy services for statin initiation and management will be generated.
Study NCT05290363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A 51 mL blood sample will be collected during the study
Study NCT05290363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: synovial aspiration
Description: If synovial aspiration is required in standard care for patients with peripheral spondylarthritis. Medical waste product will be collected for the study
Study NCT05374304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool
Description: The BC/WC framework guides clinicians to present a choice between two options and uses scenario planning (narrative descriptions of plausible outcomes that acknowledge uncertainty) to describe the best, worst, and most likely case for each option. Scenarios are informed by clinical judgement and knowledge of patient risk factors. These scenarios plus an accompanying graphic aid help patients formulate and express preferences and concerns about treatment burdens and outcomes. The clinician then provides a goal-concordant recommendation.
Study NCT05824507 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial aspiration biopsies for CE diagnosis
Description: 1 ml of aspirate will be taken from the uterine cavity for histopathological examination and immunohistochemistry for CE during general anesthesia for scheduled surgery
Study NCT06301516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: VR: The goal of the VR intervention is to provide youth an immersive, engaging, and therapeutic environment to reduce CD and CU traits
Study NCT06301516 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparative Control
Description: Complete a one-time PowerPoint presentation that provides an overview of emotion expressions and instructions on how to recognize emotions in others.
Study NCT06247306 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: ScanSTRESS fMRI-paradigm (Streit et al., 2014)
Description: The task is conducted within the MRI scanner and consists of two runs each lasting 11:20 mins., employs a block design and has two different conditions (performance, relaxation), as well as two different task within each condition. Participants undergo the following 2 tasks during the performance condition under time pressure: 1) serial subtraction, 2) a figure matching task. During the performance condition, all participants receive feedback (work faster, mistake, too slow) and are reprimanded concerning their performance. Two investigators in white coats observe the participants with critical facial expression, which is projected to participants through live-video feed during the tasks. The relaxation condition includes easy versions of arithmetic and figure matching task without time constrains or any type feedback on their performance. Performance and relaxation phases are appear in alternating order.